Hereditary angioedema therapy reference (2026)
Reference snapshot of HAE prophylaxis and on-demand therapy options.
Hereditary angioedema therapy in 2026 spans long-term prophylaxis and on-demand therapy.
Long-term prophylaxis options: lanadelumab (sub-cutaneous monoclonal antibody plasma kallikrein inhibitor, every 2 to 4 weeks), C1 esterase inhibitor concentrate (intravenous or sub-cutaneous), berotralstat (oral once-daily plasma kallikrein inhibitor). Late-stage oral options include follow-on plasma kallikrein inhibitors and factor XIIa inhibitor programs.
On-demand therapy for acute attacks: C1 esterase inhibitor concentrate (intravenous), icatibant (sub-cutaneous bradykinin receptor antagonist), ecallantide (sub-cutaneous plasma kallikrein inhibitor), sebetralstat (oral plasma kallikrein inhibitor for on-demand use, late-stage and emerging).
The modern prophylaxis tier has substantially reduced attack frequency for most patients. Diagnosis and patient identification remain a structural issue; HAE is often misattributed to allergic angioedema for years before correct identification, with C1-esterase-inhibitor activity testing as the diagnostic gate.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.